EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Anticoagulation Therapy in Advanced Chronic Kidney Disease: Balancing Bleeding and Thromboembolic Risk

Ioana Livia Suliman, Liliana-Ana Tuta iD, Camelia Pana, Florin Gabriel Panculescu, Andreea Alexandru iD, Dragos Fasie, Bogdan Cimpineanu, Stere Popescu, Florin-Daniel Enache iD, Radu Adrian Nitu, Tatiana Chisnoiu iD, Marius Florentin Popa iD und 5 weitere

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27062577 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Ioana Livia Suliman und 16 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, "Ovidius" University of Constanta, 900470 Constanta, Romania. Hauptthemen laut MEDLINE: Hemorrhage, Thromboembolism, Pyrazoles, Pyridones. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advanced chronic kidney disease (CKD) presents a complex hemostatic paradox, characterized by a simultaneous increase in bleeding and thromboembolic risks. This study aimed to evaluate and compare the safety and efficacy of apixaban versus acenocoumarol in a real-world cohort of patients across advanced CKD stages (pre-dialysis and hemodialysis). We conducted a retrospective observational study including 84 adults with CKD stages 4 and 5 (40.5% in stage 4; 59.5% in stage 5, of whom 86.0% were on chronic hemodialysis) receiving oral anticoagulation for at least 3 months. Patients were stratified by CKD stage and anticoagulant type (apixaban vs. acenocoumarol). Clinical outcomes included major and clinically relevant bleeding, anticoagulant overdose, and thromboembolic events. Bleeding events were more frequent in CKD stage 5 than in stage 4 (66.0% vs. 44.1%, p = 0.06), highlighting a pronounced hemorrhagic burden that increases with disease progression. Apixaban was associated with significantly fewer total bleeding events (44.4% vs. 66.7%, p = 0.04) and a lower rate of anticoagulant overdoses (5.6% vs. 18.8%, p = 0.04) compared with acenocoumarol. Thromboembolic event rates did not differ significantly between the two anticoagulant groups (13.9% vs. 16.7%, p = 0.72). Conventional risk scores (CHA2DS2-VASc and HAS-BLED) showed limited discriminatory capacity for actual clinical events in this advanced CKD population. In patients with advanced CKD, oral anticoagulation is associated with a high hemorrhagic burden that intensifies as renal function declines. Apixaban demonstrated a more favorable safety profile than acenocoumarol without a loss of thromboembolic protection. These findings suggest that stage-specific biological factors, rather than conventional risk models alone, should guide anticoagulation strategies in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HemorrhageThromboembolismPyrazolesPyridonesAnticoagulantsRenal Insufficiency, ChronicAcenocoumarolHumansFemaleMaleRetrospective StudiesAgedMiddle AgedRisk FactorsRenal Dialysis

Stichwörter der Autor:innen

anticoagulationapixabanbleedingchronic kidney diseasehemodialysisthrombosis

Substanzen

apixabanPyrazolesPyridonesAnticoagulantsAcenocoumarol

Autor:innen und Institutionen

  • Faculty of Medicine, "Ovidius" University of Constanta, 900470 Constanta, Romania.
  • "Sfantul Apostol Andrei" Emergency County Clinical Hospital, 900591 Constanta, Romania.
  • Center for Research and Development of the Morphological and Genetic Studies of Malignant Pathology (CEDMOG), "Ovidius" University of Constanta, 900591 Constanta, Romania.
  • Academy of Romanian Scientist, 3 Ilfov Street, 050044 Bucharest, Romania.

ORCID-Profile: Liliana-Ana Tuta, Andreea Alexandru, Florin-Daniel Enache, Tatiana Chisnoiu, Marius Florentin Popa, Mihaela Lavinia Mihai, Sorin Deacu, Georgeta Camelia Cozaru

Zitieren

APA

Suliman, I. L., Tuta, L. A., Pana, C., Panculescu, F. G., Alexandru, A., Fasie, D., Cimpineanu, B., Popescu, S., Enache, F. D., Nitu, R. A., Chisnoiu, T., Popa, M. F., Tudor, I. C., Mihai, M. L., Deacu, S., Cozaru, G. C., & Bordeianu, I. (2026). Anticoagulation Therapy in Advanced Chronic Kidney Disease: Balancing Bleeding and Thromboembolic Risk. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27062577

Vancouver

Suliman IL, Tuta LA, Pana C, Panculescu FG, Alexandru A, Fasie D, et al. Anticoagulation Therapy in Advanced Chronic Kidney Disease: Balancing Bleeding and Thromboembolic Risk. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27062577

BibTeX
@article{Suliman2026,
  author = {Suliman, Ioana Livia and Tuta, Liliana-Ana and Pana, Camelia and Panculescu, Florin Gabriel and Alexandru, Andreea and Fasie, Dragos and Cimpineanu, Bogdan and Popescu, Stere and Enache, Florin-Daniel and Nitu, Radu Adrian and Chisnoiu, Tatiana and Popa, Marius Florentin and Tudor, Iuliana-Cezara and Mihai, Mihaela Lavinia and Deacu, Sorin and Cozaru, Georgeta Camelia and Bordeianu, Ion},
  title = {Anticoagulation Therapy in Advanced Chronic Kidney Disease: Balancing Bleeding and Thromboembolic Risk},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27062577}
}
Kostenlos starten →